MTOR and breast carcinoma: Through proteomic analysis of both LMW-E-overexpressing hMECs and tumor tissue from breast cancer patients, we identify the b-Raf-ERK1/2-mTOR pathway to be critical in the tumorigenic properties of LMW-E.